Maravai Lifesciences Holdings, Inc. Class A (MRVI)

Maravai LifeSciences Holdings, Inc. stock has experienced several notable events in the past six months. The stock price increased by 49.2% from January 1st, 2026, to May 9th, 2026, trading at $4.85. Over the past year, the stock is up 26% and has reached a new 1-year high. Maravai reported strong first-quarter results, with total revenue up 41% year-over-year to $65.8 million, beating consensus estimates. Following the strong Q1 performance, Maravai raised its full-year 2026 revenue guidance to a range of $205.0 million to $215.0 million and adjusted EBITDA guidance to $30.0 million to $32.0 million. The company's stock reached a new 1-year high following an analyst upgrade. Maravai LifeSciences Holdings, Inc. reported a goodwill impairment of $11,912,000 for the fourth quarter ended December 31, 2024.

Specific detailed demand seasonality for Maravai LifeSciences' products and services is not explicitly provided. The company has indicated that its operating results are prone to significant fluctuation, which can make future operating results difficult to predict. Demand can be influenced by the lifecycle and success of vaccine programs. The Q1 2026 results showed that TriLink revenue was significantly driven by high-volume CleanCap orders for commercial phase COVID vaccine programs, indicating that large-scale vaccine initiatives can create substantial, though potentially fluctuating, demand.

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products and services for drug therapies, vaccines, diagnostics, and disease research. The company operates in the Pharmaceuticals & Biotech sector and the Life Sciences Tools and Services industry, supporting biopharmaceutical development from discovery to commercialization. Its major brands include TriLink BioTechnologies, Cygnus Technologies, Glen Research, and Alphazyme, offering products like RNA synthesis, bioprocess impurity detection, specialty reagents, and molecular biology enzymes.

Maravai LifeSciences Holdings, Inc. is headquartered in San Diego, California, United States. The company has a global reach, providing its products and services across North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin and Central America.

Maravai LifeSciences has maintained a strong brand reputation within the life sciences industry. The company and its brands are recognized as proven catalysts for developing novel vaccines, therapeutics, and diagnostics, and are considered standard-setting in their products and services. Their portfolio companies are ISO-9001:2015 certified and have been cited hundreds of thousands of times in peer-reviewed scientific publications. The recent strong financial performance in Q1 2026 further contributes positively to its reputation. The goodwill impairment reported for Q4 2024 could be a minor event that might have briefly impacted financial perception.

Maravai LifeSciences Holdings, Inc. has significant institutional ownership, with 171 institutional owners holding 127,712,038 shares, accounting for approximately 89.61% of shares outstanding, while insider ownership is around 6.7%. Major institutional owners include GTCR LLC, BlackRock, Inc., and Vanguard Group Inc. The largest individual shareholder is GTCR Investment XI LLC, owning 146.39 million shares, representing 56.95% of the company.